PURE Financials Monday, July 14, 2014 10:57:18 PM
Post# of 24
PURE Bioscience
Period Ending Jul 31, 2013 Jul 31, 2012 Jul 31, 2011 Jul 31, 2010
Total Revenue 820 812 464 1,436
Cost of Revenue 565 264 131 465
Gross Profit 255 548 333 971
Operating Expenses
Research and Development 1,325 1,863 2,180 1,927
Sales, General and Admin. 5,718 7,439 6,520 5,862
Non-Recurring Items 551 - - 93
Other - - - -
Operating Income (7,339) (8,754) (8,367) (6,911)
Income From Continuing Operations
Add'l Income/Expense Items 261 8 18 151
Earnings Before Interest and Tax (7,671) (8,890) (8,349) (6,760)
Interest Expense - - - -
Earnings Before Tax (7,671) (8,890) (8,349) (6,760)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (7,671) (8,890) (8,349) (6,760)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (7,671) (8,890) (8,349) (6,760)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (7,671) (8,890) (8,349) (6,760)